Gallium-68 labeled Ubiquicidin derived octapeptide as a potential infection imaging agent

Bhatt, Jyotsna; Mukherjee, Archana; Shinto, Ajit; Karuppusamy, Kamaleshwaran K; Korde, Aruna; Kumar, Mukesh; Sarma, Haladhar Dev; Repaka, Krishnamohan; Dash, Ashutosh

doi:10.1016/j.nucmedbio.2018.04.003

Cited by 19 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From preclinical studies in vivo it has been shown that 99m Tc-UBI 29-41 (coordination unknown) and 99m Tc-HYNIC UBI 29-41 (Scheme 4) accumulated specifically in infected tissues with abscessto-muscle ratios between 2 and 3 [14,56,57]. Both recently developed PET analogues 68 Ga-NOTA-UBI 29-41 [12,[58][59][60][61] and 68 Ga-NOTA-UBI 31-38 [62] showed comparable uptake characteristics in infected thigh muscles in mice and rabbits. However, UBI 29-41 also accumulated in infections with the yeast C. albicans [63], which reduces specificity of this tracer for imaging of bacterial infections alone.…”

Section: Imaging Of Infections With Antimicrobial Peptidesmentioning

confidence: 99%

An update on radiotracer development for molecular imaging of bacterial infections

Welling

Hensbergen

Bunschoten

et al. 2019

Clin Transl Imaging

View full text Add to dashboard Cite

Background Bacterial infections are still a major global healthcare problem. To combat the increasing antimicrobial resistance, early diagnosis of bacterial infections-including the identification of bacterial species-is needed to improve antibiotic stewardship and to help reduce the use of broad-spectrum antibiotics. To aid successful targeted antibiotic treatment, specific detection and localisation of infectious organisms is warranted. Nuclear medicine imaging approaches have been successfully used to diagnose bacterial infections and to differentiate between pathogen induced infections and sterile inflammatory processes. Aim In this comprehensive review we present an overview of recent developments in radiolabelled bacterial imaging tracers. Methods The PubMed/MEDLINE and Embase (OvidSP) literature databases were systematically searched for publications on SPECT and PET on specific imaging of bacterial using specific guidelines with MeSH-terms, truncations, and completion using cross-references. Tracers in literature that was extensively reviewed before 2016 were not included in this update. Where possible, the chemical structure of the radiolabelled compounds and clinical images were shown. Results In 219 original articles pre-clinical and clinical imaging of bacterial infection with new tracers were included. In our view, the highest translational potential lies with tracers that are specific to target the pathogens: e.g., 99m Tc-and 68 Galabelled UBI 29-41 , 99m Tc-vancomycin, m-[ 18 F]-fluoro-PABA, [methyl-11 C]-D-methionine, [ 18 F]-FDS, [ 18 F]-maltohexaose and [ 18 F]-maltotriose. An encouraging note is that some of these tracers have already been successfully evaluated in clinical settings. Conclusion This review summarises updates in tracer development for specific (pre-clinical and clinical) imaging of bacterial infections. We propsed some promising tracers that are likely to become innovative standards in the clinical setting in the near feature.

show abstract

Section: Imaging Of Infections With Antimicrobial Peptidesmentioning

confidence: 99%

An update on radiotracer development for molecular imaging of bacterial infections

Welling

Hensbergen

Bunschoten

et al. 2019

Clin Transl Imaging

View full text Add to dashboard Cite

show abstract

“…However, the reference standard for the preclinical trials are difficult to assess and the patient cases were highly selected and with very different infectious sites with no data presented on the underlying infections afterwards. The authors concluded that the method is promising, but still needs further validation [28].…”

Section: Resultsmentioning

confidence: 99%

“…In particular, the ubiquicidin peptide fragments, both UBI-31-38 and UBI-29-41, allowed to image foci of S. aureus infection in preclinical models with high T/NT ratios. Recently, UBI fragments were tested in humans and revealed to be safe and non-toxic, although further studies are needed to confirm preliminary results [28,32,44,51]. Other radiopharmaceuticals, like [ 124 I]FIAU, were less encouraging when translated to patients despite initial promising results in animals [40].…”

Section: Discussionmentioning

confidence: 99%

PET Radiopharmaceuticals for Specific Bacteria Imaging: A Systematic Review

Auletta

Varani

Horvat

et al. 2019

JCM

View full text Add to dashboard Cite

Background: Bacterial infections are still one of the main factors associated with mortality worldwide. Many radiopharmaceuticals were developed for bacterial imaging, both with single photon emission computed tomography (SPECT) and positron emission tomography (PET) isotopes. This review focuses on PET radiopharmaceuticals, performing a systematic literature review of published studies between 2005 and 2018. Methods: A systematic review of published studies between 2005 and 2018 was performed. A team of reviewers independently screened for eligible studies. Because of differences between studies, we pooled the data where possible, otherwise, we described separately. Quality of evidence was assessed by Quality Assessment of Diagnostic Accuracy Studies (QUADAS) approach. Results: Eligible papers included 35 published studies. Because of the heterogeneity of animal models and bacterial strains, we classified studies in relation to the type of bacterium: Gram-positive, Gram-negative, Gram-positive and negative, others. Conclusions: Results highlighted the availability of many promising PET radiopharmaceuticals for bacterial imaging, despite some bias related to animal selection and index test, but few have been translated to human subjects. Results showed a lack of standardized infection models and experimental settings.

show abstract

“…Indeed, biodistribution studies with 68 Ga-NOTA-UBI 31-38 revealed a specific uptake of the complex in infected muscle, compared to inflamed muscle. This was the first report on 68 Ga labelled NOTA-UBI 31-38 fragment for prospective infection imaging [48].…”

Section: Imaging Bacteria In Humansmentioning

confidence: 92%

Imaging Bacteria with Radiolabelled Probes: Is It Feasible?

Artiko

Conserva

Ferro-Flores

et al. 2020

JCM

View full text Add to dashboard Cite

Bacterial infections are the main cause of patient morbidity and mortality worldwide. Diagnosis can be difficult and delayed as well as the identification of the etiological pathogen, necessary for a tailored antibiotic therapy. Several non-invasive diagnostic procedures are available, all with pros and cons. Molecular nuclear medicine has highly contributed in this field by proposing several different radiopharmaceuticals (antimicrobial peptides, leukocytes, cytokines, antibiotics, sugars, etc.) but none proved to be highly specific for bacteria, although many agents in development look promising. Indeed, factors including the number and strain of bacteria, the infection site, and the host condition, may affect the specificity of the tested radiopharmaceuticals. At the Third European Congress on Infection/Inflammation Imaging, a round table discussion was dedicated to debate the pros and cons of different radiopharmaceuticals for imaging bacteria with the final goal to find a consensus on the most relevant research steps that should be fulfilled when testing a new probe, based on experience and cumulative published evidence.

show abstract

Gallium-68 labeled Ubiquicidin derived octapeptide as a potential infection imaging agent

Cited by 19 publications

References 24 publications

An update on radiotracer development for molecular imaging of bacterial infections

An update on radiotracer development for molecular imaging of bacterial infections

PET Radiopharmaceuticals for Specific Bacteria Imaging: A Systematic Review

Imaging Bacteria with Radiolabelled Probes: Is It Feasible?

Contact Info

Product

Resources

About